[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$ucbjf
$ucbjf sees a surge in engagements and mentions, driven by positive news regarding FDA Breakthrough Therapy Designation for relutrigine.
About $ucbjf
A financial asset.
Insights #
- $ucbjf engagements is at XXXXX which is XXX% higher than it's daily average.
- $ucbjf mentions is up XXX% from the previous month.
- $ucbjf Creators hit a high of X for the day
- $ucbjf Creators hit an all time of X for the day
Engagements: XXXXX #
Engagements 24-Hour Chart Data
Current Value: XXXXX
Daily Average: XXX
1 Month: XXXXX +22,073%
1-Year High: XXXXX on 2025-07-10
1-Year Low: X on 2025-05-08
| Social Network | X |
|---|---|
| Engagements | XXXXX |
Mentions: X #
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1 Week: X +33%
1 Month: X +100%
1-Year High: X on 2025-05-02
1-Year Low: X on 2025-04-28
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $ucbjf in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1 Week: X no change
1 Month: X +100%
1-Year High: X on 2025-07-13
1-Year Low: X on 2025-04-28
The most influential creators that mention $ucbjf in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Quantumup1 | X | XXXXX | X | XXXXX |
Sentiment: undefined% #
Top assets mentioned In the posts about $ucbjf in the last XX hours
Biogen Inc (BIIB) Neurocrine Biosciences, Inc. (NBIX)
Top topics mentioned In the posts about $ucbjf in the last XX hours
$biib, $aqst, investment, $nbix, stocks, $abgsf, $ovchf, $saxpy, $mnsaf, nyc
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"H.C. Wainwright reitd $PRAX Buy-$105 after Praxis announced that FDA had granted Breakthrough Therapy Designation (BTD) for relutrigine for the treatment of pediatric patients with SCN2A and SCN8A DEEs. $RAPP $XENE $BHVN $DRUG $NBIX ( $LBPH - $HLBBF $HLUBF) H.C. Wainwright said in its note: "While investor attention has largely been on the upcoming readout of vormatrigine's RADIANT study in focal onset seizures there has been increasing appreciation that relutrigine is deserving of attention. There's a case to be made that relutrigine's commercial potential in DEEs may even exceed"
@Quantumup1 on X 2025-07-18 12:42:09 UTC 3521 followers, 1330 engagements